INM

#4956
InMed Pharmaceuticals Inc. - Common Shares
1.3 5 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.35
1.35
Jahresspanne
0.58
2.50
Tagesänderung
-2.17%
Monatliche Änderung
-8.16%
6 month change
+60.71%
Jahresänderung
-36.92%
Vorheriger Schlusskurs
1.3 8
Open
1.3 5
Tief
1.3 5
Hoch
1.3 5
Volumen
1
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Inmed Pharmaceuticals Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Inmed Pharmaceuticals Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Inmed Pharmaceuticals Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Inmed Pharmaceuticals Inc. current report, Q1 FY2026
8-K

Inmed Pharmaceuticals Inc. current report, Q2 FY2025

Full document

Business Context and Reporting Period

Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 25, 2025
Reporting Period: Specific event date of April 25, 2025.
Context: The Company, an emerging growth company incorporated in British Columbia and listed on Nasdaq (Symbol: INM), filed this report to disclose the cancellation of a previously scheduled special meeting of shareholders.

Key Financial Metrics

This filing is a current report regarding a corporate governance event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

  • Cancellation of Shareholder Meeting: On April 25, 2025, Odyssey Trust Company, acting as agent for the Company, filed an "Amended Notice" with Canadian securities authorities (SEDAR+).
  • Effect of Change: The Amended Notice cancels the "Original Notice" which had set the date for a special meeting of shareholders and the associated record date.

Guidance, Outlook, and Risks

Management Commentary: The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business operations or strategy beyond the administrative cancellation of the meeting.

Risks and Contingencies: No specific risks or contingencies are detailed in this document. The filing includes a standard disclaimer stating that the information furnished in Item 8.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  • Verify the reason for the cancellation of the special shareholder meeting by reviewing the attached Exhibit 99.1 (Amended Notice of Meeting and Record Date).
  • Confirm if a new date for the special meeting has been scheduled in subsequent filings or press releases.
  • Review the Company's most recent 10-K or 10-Q filings for the latest financial position, as this 8-K contains no financial data.

Nachrichten